US patent on Parkinson’s disease granted

BioArctic’s patent application encompassing treatment of Parkinson’s disease was granted in US 2016-04-19. The patent (US 9,315,569) covers treatment of Parkinson’s disease with an antibody selective for α-synuclein protofibrils/oligomers which are toxic forms of α-synuclein believed to cause Parkinson’s disease.

Together with a previous granted Parkinson’s disease US patent (US 8,809,506), this patent provides a strong protection of the company’s proprietary therapeutic principle to treat the disease.